Amicus Therapeutics, Inc. (NASDAQ:FOLD) Weekly Ratings as of May 17, 2018

May 17, 2018 - By Clyde Turner

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.21. That’s change of 1.12, from 2017Q3’s 2.33. 25 investors sold all, 48 reduced holdings as Amicus Therapeutics, Inc. ratio is negative. 63 grew positions while 25 funds took positions. Funds hold 197.59 million shares thus 2.54% more from 2017Q3’s 192.70 million shares.
Omega reported 100,000 shs or 0.05% of all its holdings. Palo Alto Invsts stated it has 6.01 million shs. Dekabank Deutsche Girozentrale holds 0.01% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 70,900 shs. 217,754 are owned by Td Asset Inc. Ardsley Advisory Prtn owns 330,000 shs for 0.58% of their capital. Wells Fargo Mn holds 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 771,905 shs. Parametric Port Assoc has invested 0% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Fortaleza Asset Inc stated it has 0.65% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Art Limited Liability Com reported 0.03% stake. Mckinley Capital Management Lc Delaware holds 0.09% or 121,303 shs in its capital. Commercial Bank Of Mellon holds 0% or 879,536 shs in its capital. Smith Asset Gru Limited Partnership reported 31,400 shs or 0.01% of all its holdings. 128,498 were accumulated by Pnc Finance Grp. Pacad Invest Limited reported 3,700 shs. California State Teachers Retirement System holds 263,224 shs.

Amicus Therapeutics, Inc. had 18 insider sales and 3 buys since December 11, 2017. This’s net activity of $3.87 million. On Tuesday, January 2 Andrews Kurt J. sold $147,191 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 10,000 shs. $750,000 worth of stock was sold by Do Hung on Tuesday, April 17. On Thursday, April 12 Barth Jay also sold $73,602 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD). On Monday, April 2 $142,648 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Baird William D III. 20,000 shs valued at $300,002 were sold by HAYDEN DONALD J JR on Tuesday, January 2. 5,000 shs were sold by RAAB MICHAEL, worth $72,058 on Monday, April 16.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

In total 2 analysts cover Amicus Therapeutics (NASDAQ:FOLD). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:FOLD)’s analyst reports since February 8, 2018 according to StockzIntelligence Inc. On Wednesday, February 7 Robert W. Baird maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) with “Buy” rating. On Thursday, February 8 the rating was maintained by Leerink Swann with “Outperform”. Listed here are Amicus Therapeutics, Inc. (NASDAQ:FOLD) PTs and latest ratings.

07/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $20.0 Maintain
08/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $20 New Target: $24 Maintain

FOLD touched $16.06 during the last trading session after $1.35 change.Amicus Therapeutics, Inc. is uptrending after having risen 90.40% since May 17, 2017. FOLD has 3.20M volume or 19.83% up from normal. The stock outperformed the S&P 500 by 78.85%.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases.The company has $3.03 billion market cap. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies.Currently it has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.